Search

everythinglearnresearchcommunity

for

Search:↓

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Minoxidil caused a severe rash in a patient, which improved after stopping the drug.

Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.

A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.

Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.

AH-001 could be a safer and more effective treatment for hair loss.

Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.

Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.

Retinoids can change the hair growth cycle by extending the growth phase and shortening the rest phase.

RXR agonists may promote hair growth in humans.

Brentuximab vedotin chemotherapy can cause long-term hair loss and emotional distress.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Sorafenib can cause a unique skin reaction.

Cetuximab can cause eyelash growth, which is rare but manageable.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.